1	4	_	_	CD	_	_	_	_	_
2	.	_	_	.	_	_	_	_	_


1	Discussion	_	_	NN	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	well-characterized	_	_	JJ	_	_	_	_	_
3	GWI	_	_	NN	_	_	_	_	_
4	symptoms	_	_	NNS	_	_	_	_	_
5	are	_	_	VBP	_	_	_	_	_
6	GI	_	_	NN	_	_	_	_	_
7	inflammatory	_	_	JJ	_	_	_	_	_
8	disease	_	_	NN	_	_	_	_	_
9	,	_	_	,	_	_	_	_	_
10	chronic	_	_	JJ	_	_	_	_	_
11	fatigue	_	_	NN	_	_	_	_	_
12	,	_	_	,	_	_	_	_	_
13	neuroinflammation	_	_	NN	_	_	_	_	_
14	,	_	_	,	_	_	_	_	_
15	and	_	_	CC	_	_	_	_	_
16	cognitive	_	_	JJ	_	_	_	_	_
17	impairment	_	_	NN	_	_	_	_	_
18	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	current	_	_	JJ	_	_	_	_	_
3	study	_	_	NN	_	_	_	_	_
4	investigates	_	_	VBZ	_	_	_	_	_
5	a	_	_	DT	_	_	_	_	_
6	mechanistic	_	_	JJ	_	_	_	_	_
7	analysis	_	_	NN	_	_	_	_	_
8	of	_	_	IN	_	_	_	_	_
9	the	_	_	DT	_	_	_	_	_
10	gut	_	_	NN	_	_	_	_	_
11	virome-bacteriome	_	_	NN	_	_	_	_	_
12	mediated	_	_	VBN	_	_	_	_	_
13	GI	_	_	NN	_	_	_	_	_
14	and	_	_	CC	_	_	_	_	_
15	neuroinflammation	_	_	NN	_	_	_	_	_
16	.	_	_	.	_	_	_	_	_


1	To	_	_	TO	_	_	_	_	_
2	our	_	_	PRP$	_	_	_	_	_
3	knowledge	_	_	NN	_	_	_	_	_
4	,	_	_	,	_	_	_	_	_
5	this	_	_	DT	_	_	_	_	_
6	is	_	_	VBZ	_	_	_	_	_
7	the	_	_	DT	_	_	_	_	_
8	first	_	_	JJ	_	_	_	_	_
9	study	_	_	NN	_	_	_	_	_
10	that	_	_	WDT	_	_	_	_	_
11	examined	_	_	VBD	_	_	_	_	_
12	GW	_	_	NNP	_	_	_	_	_
13	chemical-induced	_	_	JJ	_	_	_	_	_
14	virome	_	_	NN	_	_	_	_	_
15	dysbiosis	_	_	NN	_	_	_	_	_
16	and	_	_	CC	_	_	_	_	_
17	bacteriome-virome	_	_	NN	_	_	_	_	_
18	interactions	_	_	NNS	_	_	_	_	_
19	in	_	_	IN	_	_	_	_	_
20	GWI	_	_	NNP	_	_	_	_	_
21	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	our	_	_	PRP$	_	_	_	_	_
3	previous	_	_	JJ	_	_	_	_	_
4	study	_	_	NN	_	_	_	_	_
5	,	_	_	,	_	_	_	_	_
6	we	_	_	PRP	_	_	_	_	_
7	have	_	_	VBP	_	_	_	_	_
8	shown	_	_	VBN	_	_	_	_	_
9	that	_	_	IN	_	_	_	_	_
10	GW	_	_	NN	_	_	_	_	_
11	chemical	_	_	NN	_	_	_	_	_
12	exposure	_	_	NN	_	_	_	_	_
13	causes	_	_	VBZ	_	_	_	_	_
14	bacterial	_	_	JJ	_	_	_	_	_
15	dysbiosis	_	_	NN	_	_	_	_	_
16	and	_	_	CC	_	_	_	_	_
17	that	_	_	WDT	_	_	_	_	_
18	led	_	_	VBD	_	_	_	_	_
19	to	_	_	TO	_	_	_	_	_
20	the	_	_	DT	_	_	_	_	_
21	loss	_	_	NN	_	_	_	_	_
22	of	_	_	IN	_	_	_	_	_
23	healthy	_	_	JJ	_	_	_	_	_
24	gut	_	_	NN	_	_	_	_	_
25	bacteria	_	_	NNS	_	_	_	_	_
26	such	_	_	JJ	_	_	_	_	_
27	as	_	_	IN	_	_	_	_	_
28	Lactobacillus	_	_	NNP	_	_	_	_	_
29	and	_	_	CC	_	_	_	_	_
30	Bifidobacterium	_	_	NNP	_	_	_	_	_
31	.	_	_	.	_	_	_	_	_


1	Gut	_	_	NN	_	_	_	_	_
2	dysbiosis	_	_	NN	_	_	_	_	_
3	induced	_	_	VBD	_	_	_	_	_
4	leaky	_	_	JJ	_	_	_	_	_
5	gut	_	_	NN	_	_	_	_	_
6	symptoms	_	_	NNS	_	_	_	_	_
7	and	_	_	CC	_	_	_	_	_
8	systemic	_	_	JJ	_	_	_	_	_
9	inflammation	_	_	NN	_	_	_	_	_
10	in	_	_	IN	_	_	_	_	_
11	GWI	_	_	NNP	_	_	_	_	_
12	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	a	_	_	DT	_	_	_	_	_
3	recent	_	_	JJ	_	_	_	_	_
4	review	_	_	NN	_	_	_	_	_
5	,	_	_	,	_	_	_	_	_
6	it	_	_	PRP	_	_	_	_	_
7	has	_	_	VBZ	_	_	_	_	_
8	been	_	_	VBN	_	_	_	_	_
9	reported	_	_	VBN	_	_	_	_	_
10	that	_	_	IN	_	_	_	_	_
11	gut	_	_	NN	_	_	_	_	_
12	virome	_	_	NN	_	_	_	_	_
13	is	_	_	VBZ	_	_	_	_	_
14	the	_	_	DT	_	_	_	_	_
15	missing	_	_	VBG	_	_	_	_	_
16	link	_	_	NN	_	_	_	_	_
17	between	_	_	IN	_	_	_	_	_
18	bacterial	_	_	JJ	_	_	_	_	_
19	dysbiosis	_	_	NN	_	_	_	_	_
20	and	_	_	CC	_	_	_	_	_
21	host	_	_	NN	_	_	_	_	_
22	immunity	_	_	NN	_	_	_	_	_
23	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	same	_	_	JJ	_	_	_	_	_
3	study	_	_	NN	_	_	_	_	_
4	also	_	_	RB	_	_	_	_	_
5	described	_	_	VBD	_	_	_	_	_
6	the	_	_	DT	_	_	_	_	_
7	role	_	_	NN	_	_	_	_	_
8	of	_	_	IN	_	_	_	_	_
9	virome	_	_	NN	_	_	_	_	_
10	in	_	_	IN	_	_	_	_	_
11	TLR	_	_	NNP	_	_	_	_	_
12	signaling	_	_	NN	_	_	_	_	_
13	and	_	_	CC	_	_	_	_	_
14	GI	_	_	NN	_	_	_	_	_
15	diseases	_	_	NNS	_	_	_	_	_
16	and	_	_	CC	_	_	_	_	_
17	hence	_	_	RB	_	_	_	_	_
18	concluding	_	_	VBG	_	_	_	_	_
19	that	_	_	IN	_	_	_	_	_
20	virome	_	_	NN	_	_	_	_	_
21	analysis	_	_	NN	_	_	_	_	_
22	may	_	_	MD	_	_	_	_	_
23	lead	_	_	VB	_	_	_	_	_
24	to	_	_	TO	_	_	_	_	_
25	a	_	_	DT	_	_	_	_	_
26	novel	_	_	JJ	_	_	_	_	_
27	therapeutic	_	_	JJ	_	_	_	_	_
28	strategy	_	_	NN	_	_	_	_	_
29	for	_	_	IN	_	_	_	_	_
30	GI	_	_	NN	_	_	_	_	_
31	complications	_	_	NNS	_	_	_	_	_
32	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	above	_	_	JJ	_	_	_	_	_
3	study	_	_	NN	_	_	_	_	_
4	prompted	_	_	VBD	_	_	_	_	_
5	us	_	_	PRP	_	_	_	_	_
6	to	_	_	TO	_	_	_	_	_
7	explore	_	_	VB	_	_	_	_	_
8	the	_	_	DT	_	_	_	_	_
9	role	_	_	NN	_	_	_	_	_
10	of	_	_	IN	_	_	_	_	_
11	enteric	_	_	JJ	_	_	_	_	_
12	viruses	_	_	NNS	_	_	_	_	_
13	in	_	_	IN	_	_	_	_	_
14	GWI	_	_	NNP	_	_	_	_	_
15	pathology	_	_	NN	_	_	_	_	_
16	and	_	_	CC	_	_	_	_	_
17	as	_	_	IN	_	_	_	_	_
18	a	_	_	DT	_	_	_	_	_
19	probable	_	_	JJ	_	_	_	_	_
20	therapeutic	_	_	JJ	_	_	_	_	_
21	target	_	_	NN	_	_	_	_	_
22	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	the	_	_	DT	_	_	_	_	_
3	present	_	_	JJ	_	_	_	_	_
4	study	_	_	NN	_	_	_	_	_
5	,	_	_	,	_	_	_	_	_
6	we	_	_	PRP	_	_	_	_	_
7	found	_	_	VBD	_	_	_	_	_
8	that	_	_	IN	_	_	_	_	_
9	the	_	_	DT	_	_	_	_	_
10	GW	_	_	NNP	_	_	_	_	_
11	chemical	_	_	NN	_	_	_	_	_
12	exposure	_	_	NN	_	_	_	_	_
13	led	_	_	VBD	_	_	_	_	_
14	to	_	_	TO	_	_	_	_	_
15	an	_	_	DT	_	_	_	_	_
16	increase	_	_	NN	_	_	_	_	_
17	in	_	_	IN	_	_	_	_	_
18	virome	_	_	NN	_	_	_	_	_
19	richness	_	_	NN	_	_	_	_	_
20	and	_	_	CC	_	_	_	_	_
21	relative	_	_	JJ	_	_	_	_	_
22	abundance	_	_	NN	_	_	_	_	_
23	of	_	_	IN	_	_	_	_	_
24	dsDNA	_	_	NN	_	_	_	_	_
25	bacteriophages	_	_	NNS	_	_	_	_	_
26	Myoviridae	_	_	NNP	_	_	_	_	_
27	,	_	_	,	_	_	_	_	_
28	Siphoviridae	_	_	NNP	_	_	_	_	_
29	,	_	_	,	_	_	_	_	_
30	and	_	_	CC	_	_	_	_	_
31	Caudovirales	_	_	NNP	_	_	_	_	_
32	and	_	_	CC	_	_	_	_	_
33	decreased	_	_	VBD	_	_	_	_	_
34	relative	_	_	JJ	_	_	_	_	_
35	abundance	_	_	NN	_	_	_	_	_
36	of	_	_	IN	_	_	_	_	_
37	ssDNA	_	_	NN	_	_	_	_	_
38	bacteriophages	_	_	NNS	_	_	_	_	_
39	Microviridae	_	_	NNP	_	_	_	_	_
40	.	_	_	.	_	_	_	_	_


1	We	_	_	PRP	_	_	_	_	_
2	used	_	_	VBD	_	_	_	_	_
3	a	_	_	DT	_	_	_	_	_
4	broad-spectrum	_	_	JJ	_	_	_	_	_
5	antiviral	_	_	JJ	_	_	_	_	_
6	compound	_	_	NN	_	_	_	_	_
7	Ribavirin	_	_	NNP	_	_	_	_	_
8	to	_	_	TO	_	_	_	_	_
9	test	_	_	VB	_	_	_	_	_
10	the	_	_	DT	_	_	_	_	_
11	hypothesis	_	_	NN	_	_	_	_	_
12	that	_	_	IN	_	_	_	_	_
13	(	_	_	-LRB-	_	_	_	_	_
14	a	_	_	DT	_	_	_	_	_
15	)	_	_	-RRB-	_	_	_	_	_
16	inhibition	_	_	NN	_	_	_	_	_
17	of	_	_	IN	_	_	_	_	_
18	gut	_	_	NN	_	_	_	_	_
19	viruses	_	_	NNS	_	_	_	_	_
20	in	_	_	IN	_	_	_	_	_
21	the	_	_	DT	_	_	_	_	_
22	host	_	_	NN	_	_	_	_	_
23	may	_	_	MD	_	_	_	_	_
24	prove	_	_	VB	_	_	_	_	_
25	the	_	_	DT	_	_	_	_	_
26	role	_	_	NN	_	_	_	_	_
27	of	_	_	IN	_	_	_	_	_
28	gut	_	_	NN	_	_	_	_	_
29	virome	_	_	NN	_	_	_	_	_
30	in	_	_	IN	_	_	_	_	_
31	GWI	_	_	NN	_	_	_	_	_
32	and	_	_	CC	_	_	_	_	_
33	(	_	_	-LRB-	_	_	_	_	_
34	b	_	_	NN	_	_	_	_	_
35	)	_	_	-RRB-	_	_	_	_	_
36	antiviral	_	_	JJ	_	_	_	_	_
37	treatment	_	_	NN	_	_	_	_	_
38	may	_	_	MD	_	_	_	_	_
39	help	_	_	VB	_	_	_	_	_
40	to	_	_	TO	_	_	_	_	_
41	reconstruct	_	_	VB	_	_	_	_	_
42	and	_	_	CC	_	_	_	_	_
43	restore	_	_	VB	_	_	_	_	_
44	the	_	_	DT	_	_	_	_	_
45	virome	_	_	NN	_	_	_	_	_
46	signature	_	_	NN	_	_	_	_	_
47	in	_	_	IN	_	_	_	_	_
48	GWI	_	_	NNP	_	_	_	_	_
49	.	_	_	.	_	_	_	_	_


1	Ribavirin	_	_	NNP	_	_	_	_	_
2	has	_	_	VBZ	_	_	_	_	_
3	been	_	_	VBN	_	_	_	_	_
4	extensively	_	_	RB	_	_	_	_	_
5	used	_	_	VBN	_	_	_	_	_
6	as	_	_	IN	_	_	_	_	_
7	a	_	_	DT	_	_	_	_	_
8	therapeutic	_	_	JJ	_	_	_	_	_
9	drug	_	_	NN	_	_	_	_	_
10	in	_	_	IN	_	_	_	_	_
11	several	_	_	JJ	_	_	_	_	_
12	viral	_	_	JJ	_	_	_	_	_
13	infections	_	_	NNS	_	_	_	_	_
14	including	_	_	VBG	_	_	_	_	_
15	Paramyxovirus	_	_	NNP	_	_	_	_	_
16	,	_	_	,	_	_	_	_	_
17	Adenovirus	_	_	NNP	_	_	_	_	_
18	,	_	_	,	_	_	_	_	_
19	and	_	_	CC	_	_	_	_	_
20	RSV	_	_	NN	_	_	_	_	_
21	infections	_	_	NNS	_	_	_	_	_
22	.	_	_	.	_	_	_	_	_


1	Our	_	_	PRP$	_	_	_	_	_
2	results	_	_	NNS	_	_	_	_	_
3	showed	_	_	VBD	_	_	_	_	_
4	that	_	_	IN	_	_	_	_	_
5	Ribavirin	_	_	NNP	_	_	_	_	_
6	reverses	_	_	VBZ	_	_	_	_	_
7	GWI-induced	_	_	JJ	_	_	_	_	_
8	alterations	_	_	NNS	_	_	_	_	_
9	of	_	_	IN	_	_	_	_	_
10	the	_	_	DT	_	_	_	_	_
11	enteric	_	_	JJ	_	_	_	_	_
12	viral	_	_	JJ	_	_	_	_	_
13	community	_	_	NN	_	_	_	_	_
14	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	enteric	_	_	JJ	_	_	_	_	_
3	bacteriophage-bacteria	_	_	NN	_	_	_	_	_
4	(	_	_	-LRB-	_	_	_	_	_
5	parasite-host	_	_	NN	_	_	_	_	_
6	)	_	_	-RRB-	_	_	_	_	_
7	interaction	_	_	NN	_	_	_	_	_
8	is	_	_	VBZ	_	_	_	_	_
9	an	_	_	DT	_	_	_	_	_
10	essential	_	_	JJ	_	_	_	_	_
11	phenomenon	_	_	NN	_	_	_	_	_
12	to	_	_	TO	_	_	_	_	_
13	regulate	_	_	VB	_	_	_	_	_
14	both	_	_	CC	_	_	_	_	_
15	bacterial	_	_	JJ	_	_	_	_	_
16	and	_	_	CC	_	_	_	_	_
17	viral	_	_	JJ	_	_	_	_	_
18	community	_	_	NN	_	_	_	_	_
19	in	_	_	IN	_	_	_	_	_
20	the	_	_	DT	_	_	_	_	_
21	gut	_	_	NN	_	_	_	_	_
22	and	_	_	CC	_	_	_	_	_
23	play	_	_	VB	_	_	_	_	_
24	as	_	_	IN	_	_	_	_	_
25	a	_	_	DT	_	_	_	_	_
26	key	_	_	JJ	_	_	_	_	_
27	role	_	_	NN	_	_	_	_	_
28	in	_	_	IN	_	_	_	_	_
29	gut	_	_	NN	_	_	_	_	_
30	health	_	_	NN	_	_	_	_	_
31	.	_	_	.	_	_	_	_	_


1	Here	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	we	_	_	PRP	_	_	_	_	_
4	found	_	_	VBD	_	_	_	_	_
5	an	_	_	DT	_	_	_	_	_
6	independent	_	_	JJ	_	_	_	_	_
7	or	_	_	CC	_	_	_	_	_
8	cumulative	_	_	JJ	_	_	_	_	_
9	effect	_	_	NN	_	_	_	_	_
10	of	_	_	IN	_	_	_	_	_
11	both	_	_	CC	_	_	_	_	_
12	virome	_	_	NN	_	_	_	_	_
13	and	_	_	CC	_	_	_	_	_
14	bacteriome	_	_	NN	_	_	_	_	_
15	dysbiosis	_	_	NN	_	_	_	_	_
16	in	_	_	IN	_	_	_	_	_
17	weakening	_	_	NN	_	_	_	_	_
18	of	_	_	IN	_	_	_	_	_
19	GI	_	_	NN	_	_	_	_	_
20	tight	_	_	JJ	_	_	_	_	_
21	junctions	_	_	NNS	_	_	_	_	_
22	(	_	_	-LRB-	_	_	_	_	_
23	increased	_	_	VBN	_	_	_	_	_
24	Claudin-2	_	_	NNP	_	_	_	_	_
25	and	_	_	CC	_	_	_	_	_
26	decreased	_	_	VBN	_	_	_	_	_
27	ZO1	_	_	NN	_	_	_	_	_
28	and	_	_	CC	_	_	_	_	_
29	Occludin	_	_	NNP	_	_	_	_	_
30	)	_	_	-RRB-	_	_	_	_	_
31	,	_	_	,	_	_	_	_	_
32	GI	_	_	NN	_	_	_	_	_
33	inflammation	_	_	NN	_	_	_	_	_
34	(	_	_	-LRB-	_	_	_	_	_
35	increased	_	_	VBN	_	_	_	_	_
36	MCP1	_	_	NN	_	_	_	_	_
37	and	_	_	CC	_	_	_	_	_
38	IL6	_	_	NN	_	_	_	_	_
39	)	_	_	-RRB-	_	_	_	_	_
40	,	_	_	,	_	_	_	_	_
41	systemic	_	_	JJ	_	_	_	_	_
42	inflammation	_	_	NN	_	_	_	_	_
43	(	_	_	-LRB-	_	_	_	_	_
44	increased	_	_	VBN	_	_	_	_	_
45	serum	_	_	NN	_	_	_	_	_
46	IFNÎ³	_	_	NN	_	_	_	_	_
47	and	_	_	CC	_	_	_	_	_
48	IL6	_	_	NN	_	_	_	_	_
49	)	_	_	-RRB-	_	_	_	_	_
50	and	_	_	CC	_	_	_	_	_
51	neuroinflammation	_	_	NN	_	_	_	_	_
52	(	_	_	-LRB-	_	_	_	_	_
53	increased	_	_	VBN	_	_	_	_	_
54	microglia	_	_	NN	_	_	_	_	_
55	activation	_	_	NN	_	_	_	_	_
56	and	_	_	CC	_	_	_	_	_
57	brain	_	_	NN	_	_	_	_	_
58	IL6	_	_	NN	_	_	_	_	_
59	)	_	_	-RRB-	_	_	_	_	_
60	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	present	_	_	JJ	_	_	_	_	_
3	study	_	_	NN	_	_	_	_	_
4	also	_	_	RB	_	_	_	_	_
5	showed	_	_	VBD	_	_	_	_	_
6	that	_	_	IN	_	_	_	_	_
7	Ribavirin	_	_	NNP	_	_	_	_	_
8	treatment	_	_	NN	_	_	_	_	_
9	improved	_	_	VBD	_	_	_	_	_
10	GI	_	_	NNP	_	_	_	_	_
11	tight	_	_	JJ	_	_	_	_	_
12	junction	_	_	NN	_	_	_	_	_
13	assembly	_	_	NN	_	_	_	_	_
14	and	_	_	CC	_	_	_	_	_
15	subsequently	_	_	RB	_	_	_	_	_
16	decreasing	_	_	VBG	_	_	_	_	_
17	GI	_	_	NN	_	_	_	_	_
18	and	_	_	CC	_	_	_	_	_
19	neuroinflammation	_	_	NN	_	_	_	_	_
20	.	_	_	.	_	_	_	_	_


1	Interestingly	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	inducing	_	_	VBG	_	_	_	_	_
4	gut	_	_	NN	_	_	_	_	_
5	sterility	_	_	NN	_	_	_	_	_
6	by	_	_	IN	_	_	_	_	_
7	using	_	_	VBG	_	_	_	_	_
8	antibiotics	_	_	NNS	_	_	_	_	_
9	also	_	_	RB	_	_	_	_	_
10	improves	_	_	VBZ	_	_	_	_	_
11	such	_	_	JJ	_	_	_	_	_
12	GI	_	_	NN	_	_	_	_	_
13	and	_	_	CC	_	_	_	_	_
14	neurological	_	_	JJ	_	_	_	_	_
15	complications	_	_	NNS	_	_	_	_	_
16	.	_	_	.	_	_	_	_	_


1	Results	_	_	NNS	_	_	_	_	_
2	reported	_	_	VBD	_	_	_	_	_
3	here	_	_	RB	_	_	_	_	_
4	are	_	_	VBP	_	_	_	_	_
5	also	_	_	RB	_	_	_	_	_
6	strongly	_	_	RB	_	_	_	_	_
7	supported	_	_	VBN	_	_	_	_	_
8	by	_	_	IN	_	_	_	_	_
9	previous	_	_	JJ	_	_	_	_	_
10	such	_	_	JJ	_	_	_	_	_
11	studies	_	_	NNS	_	_	_	_	_
12	where	_	_	WRB	_	_	_	_	_
13	Ribavirin	_	_	NNP	_	_	_	_	_
14	or	_	_	CC	_	_	_	_	_
15	antibiotics	_	_	NNS	_	_	_	_	_
16	were	_	_	VBD	_	_	_	_	_
17	applied	_	_	VBN	_	_	_	_	_
18	as	_	_	IN	_	_	_	_	_
19	therapeutics	_	_	NNS	_	_	_	_	_
20	in	_	_	IN	_	_	_	_	_
21	other	_	_	JJ	_	_	_	_	_
22	GI	_	_	NN	_	_	_	_	_
23	complications	_	_	NNS	_	_	_	_	_
24	and	_	_	CC	_	_	_	_	_
25	neurological	_	_	JJ	_	_	_	_	_
26	illnesses	_	_	NNS	_	_	_	_	_
27	.	_	_	.	_	_	_	_	_


1	However	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	nonavailability	_	_	NN	_	_	_	_	_
4	of	_	_	IN	_	_	_	_	_
5	germ-free	_	_	JJ	_	_	_	_	_
6	and	_	_	CC	_	_	_	_	_
7	gnotobiotic	_	_	JJ	_	_	_	_	_
8	mice	_	_	NNS	_	_	_	_	_
9	or	_	_	CC	_	_	_	_	_
10	mice	_	_	NNS	_	_	_	_	_
11	completely	_	_	RB	_	_	_	_	_
12	devoid	_	_	JJ	_	_	_	_	_
13	of	_	_	IN	_	_	_	_	_
14	gut	_	_	NN	_	_	_	_	_
15	viruses	_	_	NNS	_	_	_	_	_
16	prove	_	_	VBP	_	_	_	_	_
17	to	_	_	TO	_	_	_	_	_
18	be	_	_	VB	_	_	_	_	_
19	a	_	_	DT	_	_	_	_	_
20	serious	_	_	JJ	_	_	_	_	_
21	handicap	_	_	NN	_	_	_	_	_
22	in	_	_	IN	_	_	_	_	_
23	establishing	_	_	VBG	_	_	_	_	_
24	the	_	_	DT	_	_	_	_	_
25	exact	_	_	JJ	_	_	_	_	_
26	role	_	_	NN	_	_	_	_	_
27	of	_	_	IN	_	_	_	_	_
28	viruses	_	_	NNS	_	_	_	_	_
29	in	_	_	IN	_	_	_	_	_
30	GWI	_	_	NNP	_	_	_	_	_
31	or	_	_	CC	_	_	_	_	_
32	any	_	_	DT	_	_	_	_	_
33	other	_	_	JJ	_	_	_	_	_
34	disease	_	_	NN	_	_	_	_	_
35	pathology	_	_	NN	_	_	_	_	_
36	though	_	_	IN	_	_	_	_	_
37	use	_	_	NN	_	_	_	_	_
38	of	_	_	IN	_	_	_	_	_
39	antiviral	_	_	JJ	_	_	_	_	_
40	cocktails	_	_	NNS	_	_	_	_	_
41	similar	_	_	JJ	_	_	_	_	_
42	to	_	_	TO	_	_	_	_	_
43	our	_	_	PRP$	_	_	_	_	_
44	approach	_	_	NN	_	_	_	_	_
45	have	_	_	VBP	_	_	_	_	_
46	been	_	_	VBN	_	_	_	_	_
47	shown	_	_	VBN	_	_	_	_	_
48	to	_	_	TO	_	_	_	_	_
49	serve	_	_	VB	_	_	_	_	_
50	the	_	_	DT	_	_	_	_	_
51	purpose	_	_	NN	_	_	_	_	_
52	.	_	_	.	_	_	_	_	_


1	Gut	_	_	NN	_	_	_	_	_
2	microbiome	_	_	NN	_	_	_	_	_
3	is	_	_	VBZ	_	_	_	_	_
4	a	_	_	DT	_	_	_	_	_
5	collection	_	_	NN	_	_	_	_	_
6	of	_	_	IN	_	_	_	_	_
7	trillions	_	_	NNS	_	_	_	_	_
8	of	_	_	IN	_	_	_	_	_
9	microorganisms	_	_	NNS	_	_	_	_	_
10	that	_	_	WDT	_	_	_	_	_
11	modulated	_	_	VBD	_	_	_	_	_
12	host	_	_	NN	_	_	_	_	_
13	pathology	_	_	NN	_	_	_	_	_
14	and	_	_	CC	_	_	_	_	_
15	physiology	_	_	NN	_	_	_	_	_
16	through	_	_	IN	_	_	_	_	_
17	different	_	_	JJ	_	_	_	_	_
18	mechanisms	_	_	NNS	_	_	_	_	_
19	.	_	_	.	_	_	_	_	_


1	Previous	_	_	JJ	_	_	_	_	_
2	reports	_	_	NNS	_	_	_	_	_
3	have	_	_	VBP	_	_	_	_	_
4	suggested	_	_	VBN	_	_	_	_	_
5	that	_	_	IN	_	_	_	_	_
6	the	_	_	DT	_	_	_	_	_
7	intestinal	_	_	JJ	_	_	_	_	_
8	microbiota	_	_	NN	_	_	_	_	_
9	had	_	_	VBD	_	_	_	_	_
10	a	_	_	DT	_	_	_	_	_
11	strong	_	_	JJ	_	_	_	_	_
12	influence	_	_	NN	_	_	_	_	_
13	on	_	_	IN	_	_	_	_	_
14	the	_	_	DT	_	_	_	_	_
15	mucosal	_	_	JJ	_	_	_	_	_
16	immune	_	_	JJ	_	_	_	_	_
17	system	_	_	NN	_	_	_	_	_
18	and	_	_	CC	_	_	_	_	_
19	vice	_	_	NN	_	_	_	_	_
20	versa	_	_	RB	_	_	_	_	_
21	.	_	_	.	_	_	_	_	_


1	A	_	_	DT	_	_	_	_	_
2	balanced	_	_	JJ	_	_	_	_	_
3	pathogen	_	_	NN	_	_	_	_	_
4	and	_	_	CC	_	_	_	_	_
5	commensal	_	_	JJ	_	_	_	_	_
6	microbiome	_	_	NN	_	_	_	_	_
7	composition	_	_	NN	_	_	_	_	_
8	maintain	_	_	VBP	_	_	_	_	_
9	the	_	_	DT	_	_	_	_	_
10	microbiome-host	_	_	NN	_	_	_	_	_
11	immune	_	_	JJ	_	_	_	_	_
12	homeostasis	_	_	NN	_	_	_	_	_
13	.	_	_	.	_	_	_	_	_


1	However	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	any	_	_	DT	_	_	_	_	_
4	alteration	_	_	NN	_	_	_	_	_
5	in	_	_	IN	_	_	_	_	_
6	the	_	_	DT	_	_	_	_	_
7	microbiome	_	_	NN	_	_	_	_	_
8	may	_	_	MD	_	_	_	_	_
9	activate	_	_	VB	_	_	_	_	_
10	innate	_	_	JJ	_	_	_	_	_
11	and	_	_	CC	_	_	_	_	_
12	adaptive	_	_	JJ	_	_	_	_	_
13	immune	_	_	JJ	_	_	_	_	_
14	responses	_	_	NNS	_	_	_	_	_
15	and	_	_	CC	_	_	_	_	_
16	may	_	_	MD	_	_	_	_	_
17	progress	_	_	VB	_	_	_	_	_
18	to	_	_	TO	_	_	_	_	_
19	an	_	_	DT	_	_	_	_	_
20	inflammatory	_	_	JJ	_	_	_	_	_
21	phenotype	_	_	NN	_	_	_	_	_
22	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	the	_	_	DT	_	_	_	_	_
3	present	_	_	JJ	_	_	_	_	_
4	study	_	_	NN	_	_	_	_	_
5	we	_	_	PRP	_	_	_	_	_
6	have	_	_	VBP	_	_	_	_	_
7	shown	_	_	VBN	_	_	_	_	_
8	that	_	_	IN	_	_	_	_	_
9	the	_	_	DT	_	_	_	_	_
10	GW	_	_	NNP	_	_	_	_	_
11	chemical-induced	_	_	JJ	_	_	_	_	_
12	virome	_	_	NN	_	_	_	_	_
13	richness	_	_	NN	_	_	_	_	_
14	and	_	_	CC	_	_	_	_	_
15	dysbiosis	_	_	NN	_	_	_	_	_
16	showed	_	_	VBD	_	_	_	_	_
17	a	_	_	DT	_	_	_	_	_
18	strong	_	_	JJ	_	_	_	_	_
19	association	_	_	NN	_	_	_	_	_
20	with	_	_	IN	_	_	_	_	_
21	activated	_	_	VBN	_	_	_	_	_
22	Toll-like	_	_	NNP	_	_	_	_	_
23	receptor-7	_	_	NN	_	_	_	_	_
24	(	_	_	-LRB-	_	_	_	_	_
25	TLR7	_	_	NN	_	_	_	_	_
26	)	_	_	-RRB-	_	_	_	_	_
27	and	_	_	CC	_	_	_	_	_
28	TLR9	_	_	NN	_	_	_	_	_
29	mediated	_	_	VBD	_	_	_	_	_
30	proinflammatory	_	_	JJ	_	_	_	_	_
31	pathways	_	_	NNS	_	_	_	_	_
32	.	_	_	.	_	_	_	_	_


1	We	_	_	PRP	_	_	_	_	_
2	also	_	_	RB	_	_	_	_	_
3	found	_	_	VBD	_	_	_	_	_
4	that	_	_	IN	_	_	_	_	_
5	the	_	_	DT	_	_	_	_	_
6	expression	_	_	NN	_	_	_	_	_
7	and	_	_	CC	_	_	_	_	_
8	activation	_	_	NN	_	_	_	_	_
9	of	_	_	IN	_	_	_	_	_
10	downstream	_	_	NN	_	_	_	_	_
11	signaling	_	_	VBG	_	_	_	_	_
12	molecules	_	_	NNS	_	_	_	_	_
13	including	_	_	VBG	_	_	_	_	_
14	TLR7-MyD88	_	_	NN	_	_	_	_	_
15	(	_	_	-LRB-	_	_	_	_	_
16	binding	_	_	NN	_	_	_	_	_
17	of	_	_	IN	_	_	_	_	_
18	TLR7	_	_	NN	_	_	_	_	_
19	with	_	_	IN	_	_	_	_	_
20	adaptor	_	_	NN	_	_	_	_	_
21	molecule	_	_	NN	_	_	_	_	_
22	myosin	_	_	NN	_	_	_	_	_
23	D88	_	_	NNP	_	_	_	_	_
24	)	_	_	-RRB-	_	_	_	_	_
25	,	_	_	,	_	_	_	_	_
26	TLR9-MyD88	_	_	NN	_	_	_	_	_
27	,	_	_	,	_	_	_	_	_
28	or	_	_	CC	_	_	_	_	_
29	TLR4-Flottilin	_	_	NNP	_	_	_	_	_
30	(	_	_	-LRB-	_	_	_	_	_
31	localization	_	_	NN	_	_	_	_	_
32	of	_	_	IN	_	_	_	_	_
33	TLR4	_	_	NN	_	_	_	_	_
34	in	_	_	IN	_	_	_	_	_
35	lipid	_	_	NN	_	_	_	_	_
36	raft	_	_	NN	_	_	_	_	_
37	)	_	_	-RRB-	_	_	_	_	_
38	complex	_	_	NN	_	_	_	_	_
39	formation	_	_	NN	_	_	_	_	_
40	,	_	_	,	_	_	_	_	_
41	TRAF6	_	_	NN	_	_	_	_	_
42	,	_	_	,	_	_	_	_	_
43	IKK-Î±	_	_	NN	_	_	_	_	_
44	,	_	_	,	_	_	_	_	_
45	and	_	_	CC	_	_	_	_	_
46	p65	_	_	NNP	_	_	_	_	_
47	(	_	_	-LRB-	_	_	_	_	_
48	NFÎºB	_	_	NN	_	_	_	_	_
49	activation	_	_	NN	_	_	_	_	_
50	)	_	_	-RRB-	_	_	_	_	_
51	have	_	_	VBP	_	_	_	_	_
52	been	_	_	VBN	_	_	_	_	_
53	increased	_	_	VBN	_	_	_	_	_
54	upon	_	_	IN	_	_	_	_	_
55	gut	_	_	NN	_	_	_	_	_
56	virome	_	_	NN	_	_	_	_	_
57	and	_	_	CC	_	_	_	_	_
58	microbiome	_	_	NN	_	_	_	_	_
59	dysbiosis	_	_	NN	_	_	_	_	_
60	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	dysbiosis	_	_	NN	_	_	_	_	_
3	was	_	_	VBD	_	_	_	_	_
4	also	_	_	RB	_	_	_	_	_
5	accompanied	_	_	VBN	_	_	_	_	_
6	by	_	_	IN	_	_	_	_	_
7	increased	_	_	VBN	_	_	_	_	_
8	inflammation	_	_	NN	_	_	_	_	_
9	while	_	_	IN	_	_	_	_	_
10	use	_	_	NN	_	_	_	_	_
11	of	_	_	IN	_	_	_	_	_
12	Ribavirin	_	_	NNP	_	_	_	_	_
13	or	_	_	CC	_	_	_	_	_
14	antibiotics	_	_	NNS	_	_	_	_	_
15	independently	_	_	RB	_	_	_	_	_
16	downregulated	_	_	VBD	_	_	_	_	_
17	these	_	_	DT	_	_	_	_	_
18	pathways	_	_	NNS	_	_	_	_	_
19	and	_	_	CC	_	_	_	_	_
20	subsequently	_	_	RB	_	_	_	_	_
21	inflammation	_	_	NN	_	_	_	_	_
22	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	above	_	_	JJ	_	_	_	_	_
3	results	_	_	NNS	_	_	_	_	_
4	prompted	_	_	VBD	_	_	_	_	_
5	us	_	_	PRP	_	_	_	_	_
6	to	_	_	TO	_	_	_	_	_
7	study	_	_	VB	_	_	_	_	_
8	whether	_	_	IN	_	_	_	_	_
9	virome	_	_	NN	_	_	_	_	_
10	diversity	_	_	NN	_	_	_	_	_
11	had	_	_	VBD	_	_	_	_	_
12	a	_	_	DT	_	_	_	_	_
13	direct	_	_	JJ	_	_	_	_	_
14	connection	_	_	NN	_	_	_	_	_
15	to	_	_	TO	_	_	_	_	_
16	a	_	_	DT	_	_	_	_	_
17	sustained	_	_	VBN	_	_	_	_	_
18	systemic	_	_	JJ	_	_	_	_	_
19	inflammatory	_	_	JJ	_	_	_	_	_
20	response	_	_	NN	_	_	_	_	_
21	via	_	_	IN	_	_	_	_	_
22	increased	_	_	VBN	_	_	_	_	_
23	serum	_	_	NN	_	_	_	_	_
24	IL6	_	_	NN	_	_	_	_	_
25	or	_	_	CC	_	_	_	_	_
26	vice	_	_	NN	_	_	_	_	_
27	versa	_	_	RB	_	_	_	_	_
28	.	_	_	.	_	_	_	_	_


1	We	_	_	PRP	_	_	_	_	_
2	found	_	_	VBD	_	_	_	_	_
3	that	_	_	IN	_	_	_	_	_
4	IL6	_	_	NNP	_	_	_	_	_
5	and	_	_	CC	_	_	_	_	_
6	virome	_	_	NN	_	_	_	_	_
7	diversity	_	_	NN	_	_	_	_	_
8	had	_	_	VBD	_	_	_	_	_
9	a	_	_	DT	_	_	_	_	_
10	positive	_	_	JJ	_	_	_	_	_
11	correlation	_	_	NN	_	_	_	_	_
12	in	_	_	IN	_	_	_	_	_
13	GWI	_	_	NNP	_	_	_	_	_
14	.	_	_	.	_	_	_	_	_


1	Studies	_	_	NNS	_	_	_	_	_
2	have	_	_	VBP	_	_	_	_	_
3	shown	_	_	VBN	_	_	_	_	_
4	that	_	_	IN	_	_	_	_	_
5	the	_	_	DT	_	_	_	_	_
6	enteric	_	_	JJ	_	_	_	_	_
7	viruses	_	_	NNS	_	_	_	_	_
8	can	_	_	MD	_	_	_	_	_
9	activate	_	_	VB	_	_	_	_	_
10	TLR3	_	_	NN	_	_	_	_	_
11	signaling	_	_	NN	_	_	_	_	_
12	pathway	_	_	NN	_	_	_	_	_
13	to	_	_	TO	_	_	_	_	_
14	induce	_	_	VB	_	_	_	_	_
15	anti-inflammatory	_	_	JJ	_	_	_	_	_
16	response	_	_	NN	_	_	_	_	_
17	via	_	_	IN	_	_	_	_	_
18	IFNÎ²	_	_	NNP	_	_	_	_	_
19	production	_	_	NN	_	_	_	_	_
20	.	_	_	.	_	_	_	_	_


1	However	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	it	_	_	PRP	_	_	_	_	_
4	has	_	_	VBZ	_	_	_	_	_
5	always	_	_	RB	_	_	_	_	_
6	been	_	_	VBN	_	_	_	_	_
7	a	_	_	DT	_	_	_	_	_
8	conflict	_	_	NN	_	_	_	_	_
9	whether	_	_	IN	_	_	_	_	_
10	viral-induced	_	_	JJ	_	_	_	_	_
11	TLR3	_	_	NN	_	_	_	_	_
12	activation	_	_	NN	_	_	_	_	_
13	leads	_	_	VBZ	_	_	_	_	_
14	to	_	_	TO	_	_	_	_	_
15	pro-	_	_	JJ	_	_	_	_	_
16	or	_	_	CC	_	_	_	_	_
17	anti-inflammatory	_	_	JJ	_	_	_	_	_
18	response	_	_	NN	_	_	_	_	_
19	in	_	_	IN	_	_	_	_	_
20	viral	_	_	JJ	_	_	_	_	_
21	pathogenesis	_	_	NN	_	_	_	_	_
22	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	our	_	_	PRP$	_	_	_	_	_
3	study	_	_	NN	_	_	_	_	_
4	,	_	_	,	_	_	_	_	_
5	we	_	_	PRP	_	_	_	_	_
6	observed	_	_	VBD	_	_	_	_	_
7	that	_	_	IN	_	_	_	_	_
8	increased	_	_	VBN	_	_	_	_	_
9	TLR3	_	_	NN	_	_	_	_	_
10	might	_	_	MD	_	_	_	_	_
11	switch	_	_	VB	_	_	_	_	_
12	to	_	_	TO	_	_	_	_	_
13	pro-inflammatory	_	_	JJ	_	_	_	_	_
14	response	_	_	NN	_	_	_	_	_
15	via	_	_	IN	_	_	_	_	_
16	IL6	_	_	NNP	_	_	_	_	_
17	or	_	_	CC	_	_	_	_	_
18	fail	_	_	VB	_	_	_	_	_
19	to	_	_	TO	_	_	_	_	_
20	produce	_	_	VB	_	_	_	_	_
21	significant	_	_	JJ	_	_	_	_	_
22	IFNÎ²	_	_	NN	_	_	_	_	_
23	in	_	_	IN	_	_	_	_	_
24	order	_	_	NN	_	_	_	_	_
25	to	_	_	TO	_	_	_	_	_
26	support	_	_	VB	_	_	_	_	_
27	its	_	_	PRP$	_	_	_	_	_
28	anti-inflammatory	_	_	JJ	_	_	_	_	_
29	role	_	_	NN	_	_	_	_	_
30	in	_	_	IN	_	_	_	_	_
31	GWI	_	_	NNP	_	_	_	_	_
32	though	_	_	IN	_	_	_	_	_
33	such	_	_	JJ	_	_	_	_	_
34	mechanisms	_	_	NNS	_	_	_	_	_
35	in	_	_	IN	_	_	_	_	_
36	the	_	_	DT	_	_	_	_	_
37	host	_	_	NN	_	_	_	_	_
38	remain	_	_	VBP	_	_	_	_	_
39	inconclusive	_	_	JJ	_	_	_	_	_
40	at	_	_	IN	_	_	_	_	_
41	this	_	_	DT	_	_	_	_	_
42	time	_	_	NN	_	_	_	_	_
43	.	_	_	.	_	_	_	_	_

